OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
PHILADELPHIA and OXFORD, U.K., Feb. 09, 2017 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Adrian Rawcliffe, Adaptimmune’s Chief Financial Officer, will present at the Leerink 6th Annual Global Healthcare Conference on Wednesday February 15, 2017 at 1:00 PM EST (6:00 PM BST). The conference is being held at the Lotte New York Palace Hotel. Adaptimmune’s presentation will be webcast live for investors through the investor section of www.adaptimmune.com and available for a period of 30 days following the conference.
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR® (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune has a number of proprietary clinical programs, and is also developing its NY-ESO SPEAR T-cell program under a strategic collaboration and licensing agreement with GlaxoSmithKline. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com
Adaptimmune Contacts Investor Relations Will Roberts T: (215) 825-9306 E: [email protected] Juli P. Miller, Ph.D. T: (215) 825-9310 E: [email protected] Media Relations Margaret Henry T: +44 (0)1235 430036 Mobile: +44 (0)7710 304249 E: [email protected]
